- Rating
- 1
- Confidence
- 3
- Informativeness
- 1
- Presentation
- 2
- Soundness
- 1
Read review
Paper summary
This paper proposes a target-aware drug repurposing framework based on drug-target-disease triplets. Drug, target, and disease nodes are embedded using Node2Vec on the ROBOKOP knowledge graph, and their embeddings are concatenated and fed to an MLP classifier. The authors compare triplet-based models with drug-disease doublet models, several conventional classifiers, and text-based embeddings. They report improved classification and ranking performance when target information is included, and further use the trained model to generate drug repurposing hypotheses for ALS and Huntington’s disease.
Critical strengths
S1. Explicitly incorporating molecular targets into drug repurposing is well motivated and provides a more mechanistic formulation than direct drug-disease prediction.
S2. The paper evaluates multiple classifiers and embedding types and includes ranking-based metrics and case studies for downstream drug repurposing hypotheses.
Critical weaknesses
W1. Positive and negative triplets differ structurally by construction. Positive samples form complete drug-target-disease motifs, while most negatives are created by random entity replacement. The model may therefore exploit local KG connectivity rather than learn a generalizable therapeutic relationship.
W2. The evaluation is mainly transductive. Drug-disease pairs are split, but drugs, diseases, and targets can still appear in both training and test sets, with Node2Vec embeddings learned from the same graph. Generalization to unseen entities is therefore unclear.
W3. The baseline comparison is limited for a KG-based prediction study. Standard knowledge-graph embedding and heterogeneous graph methods, such as TransE, RotatE, ComplEx, R-GCN, or HGT, are not included.
Questions for authors
Q1. How does the method perform when drugs, diseases, or targets in the test set are completely unseen during embedding and classifier training?
Q2. Could the authors compare against standard KG link-prediction methods such as TransE, RotatE, ComplEx, or heterogeneous GNN baselines under the same split?
Q3. Can the authors provide a matched DTD′ versus DD′ experiment with identical training pairs, optimization budget, and classifier capacity, differing only in whether target information is included?
Q4. How much performance can be obtained using a simple graph heuristic, such as whether the drug and disease share a target or the number of common target paths? This would help quantify how much the learned model adds beyond local KG topology.